PotBotics: Bringing Big Data to Medical Cannabis


Ryan Allway

February 20th, 2019

Exclusive, News


Most people have heard of the term ‘big data’, but few appreciate the impact that it has on everyday life. From the ads that you see to the insurance premiums you pay, big data is used to help more informed decisions across all industries. It’s not surprising then that the market for big data and business analytics is projected to reach more than $200 billion by 2020—making it one of the most important growth industries in the world.

PotBotics is a leader in applying big data to the nascent cannabis industry. With a robust AI platform that aggregates and correlates HIPAA-compliant medical data, the company helps doctors and patients personalize cannabis to better predict treatment outcomes.

Why Big Data Matters

The amount of data generated every day is almost incomprehensible. According to IDC, the total amount of data will rise to 44 zettabytes by 2020—that’s the equivalent of 250,000 Libraries of Congress or 530 million songs every day.

On a national or global level, big data is used by companies and governments to make informed decisions. Companies find prospective customers online using platforms that collect  and anonymize demographic information, such as gender, income, interests, and location, enabling highly targeted advertising campaigns. Governments may look at large datasets when making policy decisions to ensure they’re acting in everyone’s best interest.

IDC projects that worldwide revenue for big data and business analytics will grow from $130.1 billion in 2016 to more than $203 billion by 2020, representing a compound annual growth rate of 11.7 percent. Investors may want to pay attention to companies operating in the market given these significant revenue levels and projected growth rates—particularly in industries that are themselves experiencing strong growth.

Please Click Here to see an Investor Presentation

Big Data and Cannabis

The legal cannabis industry is projected to reach $146.4 billion by 2025, according to Grand View Research, driven by the legalization of medical and adult-use cannabis in North America and abroad. In the U.S., the legal cannabis market is projected to grow at a 24.9 percent compound annual growth rate between 2017 and 2025. These attributes make the market extremely attractive to growth investors.

Despite these growth rates, the cannabis industry has experienced a lot of challenges. Studies have found that one-third of cannabis strains don’t match their advertised genetics. In particular, many hybrid strains sold under the same name by multiple growers are very different from a genetic standpoint. This makes it very difficult for dispensaries and consumers to know what they’re buying and how it will affect them.

PotBotics takes the guesswork out of recommending cannabis products with a big data approach. By collecting data from cultivation to patient consumption, the company is building the largest centralized hub for medical cannabis insights and correlations. This information is analyzed using artificial intelligence and machine learning algorithms to uncover critical insights for cannabis professionals and consumers.

Physicians can use use the sophisticated patient management system to make personalized, science-backed recommendations, as well as communicate with patients. Dispensaries can use the same platform to maintain inventory that’s best-suited for treating a patient’s condition, while educating patients to provide an exceptional experience. Finally, consumers can connect with the strains that actually work for their needs.

Consumer-Level Products

PotBotics plans to further aggregate patient-level data through consumer devices, such as its RYAH dose-measuring vaporizer.

RYAH enables patients to personalize their microdosing regimen down to the ml, while controlling temperature by one degree increments. In addition, patients can save the temperature and dosing that works best for them as a preset for future sessions. The QR-enabled capsules and associated smartphone app let patients record the effect of each session and compare their experience with each capsule.

The data from the device is aggregated using the PotBot app, which is the #1 app in the U.S. App Store when searching for the term “marijuana” with over 180,000 downloads and over 70,000 users. Data from these users is stored anonymously within HIPAA standards and analyzed to produce bi-weekly reports featured on the company’s website and in its bi-weekly newsletters, providing critical insights to industry professionals.

In particular, the database helps show what strains and cannabinoids work best for specific medical conditions, as well as look for more general effects on individuals (e.g. sleep, relaxation, pain, etc.). These data points and insights could be invaluable for researchers, doctors, growers, and other individuals or companies operating in the legal cannabis industry.

Looking Ahead

PotBotics’s product and technology strategy uses pre-existing, fully-vetted, and IP-protected technology adapted and applied to the cannabis industry. With a strong patent portfolio in place, the company has a unique ability to gather and correlate data, creating the world’s first cannabinoid ontology. Since it doesn’t touch the cannabis plant, the company is also free to work in any regulatory environment with significantly less risk than more direct cannabis investments.

Please click here to see an Investor Presentation.

For more information, visit the company’s website at www.PotBotics.com.

Disclaimer

The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: https://cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading